CSF2 and renal carcinoma: Using granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant, the naked mRNA vaccine targeting several tumour-associated antigens slowed the progression of renal cancer with the induction of both CD4+ and CD8+ T cells responsive to the antigens in some patients in a clinical trial [64].